TY  - JOUR
AU  - Schober, T.
TI  - Composites of ceramic high-temperature proton conductors with inorganic compounds
JO  - Electrochemical and solid-state letters
VL  - 8
SN  - 1099-0062
CY  - Pennington, NJ
PB  - Soc.
M1  - PreJuSER-45393
SP  - A199 - A200
PY  - 2005
N1  - Record converted from VDB: 12.11.2012
AB  - This open-label extension evaluated the long-term efficacy and tolerability of rufinamide in patients with Lennox-Gastaut syndrome (LGS) who had previously completed a 12-week double-blind study.In total, 124 patients (aged 4-37 years), receiving 1-3 concomitant antiepileptic drugs, were treated with rufinamide approximately 25-60 mg/kg/day. Efficacy was assessed by seizure frequency; tolerability by adverse events (AEs) and laboratory tests.Overall, patients were treated with rufinamide for a median (range) of 432 (10-1149) days. Reductions in seizure frequency were observed throughout the study; during the last 12 months of treatment, 41.0% and 47.9% of patients had > or = 50% reduction in total and tonic-atonic seizure frequency, respectively. The most common AEs were vomiting (30.6%) and pyrexia (25.8%).In this open-label extension, rufinamide appeared to be an effective long-term adjunctive therapy for the treatment of LGS-associated seizures in children and young adults.
KW  - J (WoSType)
LB  - PUB:(DE-HGF)16
UR  - <Go to ISI:>//WOS:000228326500006
DO  - DOI:10.1149/1.1865592
UR  - https://juser.fz-juelich.de/record/45393
ER  -